Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease.

ABSTRACT:

Background

In patients with motor fluctuations complicating Parkinson's disease (PD), delays in time-to-ON with levodopa are common. This open-label study aimed to assess the effect of apomorphine on time-to-ON in PD patients with morning akinesia.

Methods

The safety population included 127 enrolled patients, and the full analysis set (FAS) included 88 patients. Patients completed a 7-day levodopa baseline period recording their time-to-ON following each morning dose of levodopa. Patients were titrated to an optimal dose of apomorphine (2-6 mg) while taking trimethobenzamide antiemetic therapy. Apomorphine was injected each morning for a 7-day treatment period and time-to-ON was self-recorded in 5-minute blocks. The primary efficacy variable was time-to-ON in the apomorphine

SUBMITTER: Isaacson S 

PROVIDER: S-EPMC5298032 | biostudies-literature | 2017 Jan-Feb

REPOSITORIES: biostudies-literature